Abstract
BackgroundTofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3 studies in patients (pts) with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have